Moderna reports strong 5-year melanoma vaccine data but stock falls amid expanded Ebola vaccine partnership.
Moderna announced positive 5-year follow-up results from its melanoma vaccine trial showing a 49% reduction in recurrence or death risk when combined with KEYTRUDA, confirming earlier findings. Despite this, Moderna's stock dropped 2.78% to $45.88. T...
